Items Tagged ‘Cabometyx’

May 10th, 2016

Cabometyx® Approved for Kidney Cancer


The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma